- Home
- BNTX vs ROIV Comparison
BNTX vs ROIV Comparison
Compare BNTX & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNTX | ROIV |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | Germany | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.7B | 28.7B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BNTX | ROIV |
|---|---|---|
| Price | $95.88 | $35.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 13 |
| Target Price | ★ $115.73 | $48.08 |
| AVG Volume (30 Days) | 792.4K | ★ 7.1M |
| Earning Date | 11-03-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,260,000.00 |
| Revenue This Year | N/A | $530.75 |
| Revenue Next Year | $0.20 | $685.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $79.81 | $15.91 |
| 52 Week High | $124.00 | $42.50 |
Technical Indicators
Market Signals| Indicator | BNTX | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 43.39 | 40.03 |
| Support Level | $95.32 | $33.15 |
| Resistance Level | $98.81 | $35.70 |
| Average True Range (ATR) | 3.00 | 1.22 |
| MACD | -0.29 | -0.46 |
| Stochastic Oscillator | 8.11 | 7.88 |
Price Performance
Historical ComparisonAbout BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.